

LACHMAN CONSULTANT SERVICES, INC.
CONSULTANTS TO THE PHARMACEUTICAL AND ALLIED INDUSTRIES

1600 STEWART AVENUE, WESTBURY, NY 11590
(516) 222-6222 • FAX (516) 683-1887

1367 5 JUN -3 A9:43

June 2, 2005

OVERNIGHT COURIER 06/2/05

Division of Dockets Management
Food and Drug Administration (HFA-305)
Department of Health and Human Services
5630 Fishers Lane, Room 1061
Rockville, MD 20852

Withdrawal of Citizen Petition 2004P-0418CP1

Dear Sir or Madam:

The above-referenced petition was submitted to the FDA on September 13, 2004 under Section 505(j)(2)(C) of the Federal Food, Drug and Cosmetic Act, and in accordance with 21 CFR 10.30. The petition requested the Commissioner of the Food and Drug Administration to declare that the drug products Atorvastatin Calcium Capsules, 10 mg, 20 mg, 40 mg and 80 mg, are suitable for submission in an abbreviated new drug application (ANDA). At this time, Lachman Consultant Services, Inc. requests that this petition be withdrawn.

Sincerely,

Handwritten signature of Robert W. Pollock in cursive, with the letters 'pk' written below the signature.

Robert W. Pollock, Vice President
Lachman Consultant Services, Inc.
1600 Stewart Avenue
Westbury, NY 11590

RWP/pk

cc: Emily Thakur (Office of Generic Drugs)

R03P5153a

2004 P-0418

WDL1

LACHMAN CONSULTANT SERVICES, INC.
CONSULTANTS TO THE PHARMACEUTICAL AND ALLIED INDUSTRIES

1600 STEWART AVENUE, WESTBURY, NY 11590
(516) 222-6222 • FAX (516) 683-1887

1368 5 JUN -3 A9:43

June 2, 2005

OVERNIGHT COURIER 06/2/05

Division of Dockets Management
Food and Drug Administration (HFA-305)
Department of Health and Human Services
5630 Fishers Lane, Room 1061
Rockville, MD 20852

Withdrawal of Citizen Petition 2004P-0418CP1

Dear Sir or Madam:

The above-referenced petition was submitted to the FDA on September 13, 2004 under Section 505(j)(2)(C) of the Federal Food, Drug and Cosmetic Act, and in accordance with 21 CFR 10.30. The petition requested the Commissioner of the Food and Drug Administration to declare that the drug products Atorvastatin Calcium Capsules, 10 mg, 20 mg, 40 mg and 80 mg, are suitable for submission in an abbreviated new drug application (ANDA). At this time, Lachman Consultant Services, Inc. requests that this petition be withdrawn.

Sincerely,



Robert W. Pollock, Vice President
Lachman Consultant Services, Inc.
1600 Stewart Avenue
Westbury, NY 11590

RWP/pk

cc: Emily Thakur (Office of Generic Drugs)

R03P5153a

LACHMAN CONSULTANT SERVICES, INC.
CONSULTANTS TO THE PHARMACEUTICAL AND ALLIED INDUSTRIES

1600 STEWART AVENUE, WESTBURY, NY 11590
(516) 222-6222 • FAX (516) 683-1887

1369 5 JUN -3 A9:43

June 2, 2005

OVERNIGHT COURIER 06/2/05

Division of Dockets Management
Food and Drug Administration (HFA-305)
Department of Health and Human Services
5630 Fishers Lane, Room 1061
Rockville, MD 20852

Withdrawal of Citizen Petition 2004P-0418CP1

Dear Sir or Madam:

The above-referenced petition was submitted to the FDA on September 13, 2004 under Section 505(j)(2)(C) of the Federal Food, Drug and Cosmetic Act, and in accordance with 21 CFR 10.30. The petition requested the Commissioner of the Food and Drug Administration to declare that the drug products Atorvastatin Calcium Capsules, 10 mg, 20 mg, 40 mg and 80 mg, are suitable for submission in an abbreviated new drug application (ANDA). At this time, Lachman Consultant Services, Inc. requests that this petition be withdrawn.

Sincerely,

Handwritten signature of Robert W. Pollock in black ink, with a small 'pk' initials to the right.

Robert W. Pollock, Vice President
Lachman Consultant Services, Inc.
1600 Stewart Avenue
Westbury, NY 11590

RWP/pk

cc: Emily Thakur (Office of Generic Drugs)

R03P5153a

LACHMAN CONSULTANT SERVICES, INC.
CONSULTANTS TO THE PHARMACEUTICAL AND ALLIED INDUSTRIES

1600 STEWART AVENUE, WESTBURY, NY 11590
(516) 222-6222 • FAX (516) 683-1887

1370 5 JUN -3 A9:43

June 2, 2005

OVERNIGHT COURIER 06/2/05

Division of Dockets Management
Food and Drug Administration (HFA-305)
Department of Health and Human Services
5630 Fishers Lane, Room 1061
Rockville, MD 20852

Withdrawal of Citizen Petition 2004P-0418CP1

Dear Sir or Madam:

The above-referenced petition was submitted to the FDA on September 13, 2004 under Section 505(j)(2)(C) of the Federal Food, Drug and Cosmetic Act, and in accordance with 21 CFR 10.30. The petition requested the Commissioner of the Food and Drug Administration to declare that the drug products Atorvastatin Calcium Capsules, 10 mg, 20 mg, 40 mg and 80 mg, are suitable for submission in an abbreviated new drug application (ANDA). At this time, Lachman Consultant Services, Inc. requests that this petition be withdrawn.

Sincerely,

Handwritten signature of Robert W. Pollock in black ink, with the initials 'pk' written below it.

Robert W. Pollock, Vice President
Lachman Consultant Services, Inc.
1600 Stewart Avenue
Westbury, NY 11590

RWP/pk

cc: Emily Thakur (Office of Generic Drugs)

R03P5153a